Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revance Therapeutics, Inc. - Common Stock (NQ: RVNC )

3.650 UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Revance Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Earnings Preview For Revance Therapeutics
Via Benzinga
Revance to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
From Revance Therapeutics, Inc.
Via Business Wire
7 Analysts Have This to Say About Revance Therapeutics
Via Benzinga
Revance to Participate in the Needham 22nd Annual Healthcare Conference
From Revance Therapeutics, Inc.
Via Business Wire
What 4 Analyst Ratings Have To Say About Revance Therapeutics
Via Benzinga
7 Stocks to Buy for the Massive Rally Ahead
With economic growth poised to exceed expectations in 2023, here are seven stocks to buy for a market rally. 
Via InvestorPlace
Revance Publishes its 2022 Environmental, Social, and Governance (ESG) Report
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in Upcoming Investor Conferences
From Revance Therapeutics, Inc.
Via Business Wire
Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor
Revance Therapeutics gapped up 54.34% on January 9, and built upon those gains in February. The company reported its first revenue for Botox competitor Daxxify. 
Via MarketBeat
Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in the 43rd Annual Cowen Healthcare Conference
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Present New Data on DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia at the Association of Academic Physiatrists Annual Meeting
From Revance Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. 
Via Benzinga
Revance to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023
From Revance Therapeutics, Inc.
Via Business Wire
3 Pharma Stocks That Will Mint Millionaires
These pharma stocks all have excellent risk-reward ratios and the companies have developed treatments that could easily become blockbusters. 
Via InvestorPlace
Here's Why This Analyst Seems Highly Convinced With Evolus' Outlook
Evolus Inc (NASDAQ: EOLS) issued fourth-quarter 2022 and full-year 2022 revenues of $43.6 million, up 26% Y/Y and approximately $148.6 million, up 49%, respectively. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Tesla, Apple, Nuwellis, Revance, Lululemon: Why These 5 Stocks Are Drawing Investors' Attention Today
Major Wall Street indices closed mixed on Monday with the Nasdaq Composite being the only one to end the session on a positive note, led by gains in technology shares. The Dow Jones and the S&P 500... 
Via Benzinga
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Tesla, Zillow, Albireo Pharma And Some Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Dow Jones gaining more than 150 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results
From Revance Therapeutics, Inc.
Via Business Wire
Macy's, Acuity Brands And 3 Stocks To Watch Heading Into Monday
With US stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference
From Revance Therapeutics, Inc.
Via Business Wire
One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID
Palm Beach, FL – November 17, 2022 – FinancialNewsMedia.com News Commentary – Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the body.... 
Via FinancialNewsMedia
Exposures COVID-19
What 8 Analyst Ratings Have To Say About Revance Therapeutics
Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Revance to Participate in the Stifel 2022 Healthcare Conference
From Revance Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback